Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Myriad Genetics, Inc.    MYGN   US62855J1043

SummaryQuotesChart AnalysisNewsAnalysisCalendarCompanyFinancialsConsensusRevisionsForum 
Analysis summary4-Traders Strategies 

Myriad Genetics, Inc. : Near a solid support area

02/19/2013 | 09:00am
Opinion : Bullish above 24.2 USD
Target price : 26.1 USD
Stop loss: 23.6 USD
NASDAQ
Pharmaceuticals - Generic / Specialty
Myriad Genetics' share price was heavily penalized and is now in an oversold situation near to a solid support area.

Myriad Genetics is technically oversold and is near to the USD 24.2 support. This situation gives credit to a potential technical rebound. Thus, the stock could find new energy and would rise towards the next USD 26.1 resistance.

So as to make the most of a potential technical rebound of Myriad Genetics, it seems opportune to take a long position at the current price. A confirmation of this pattern would enable the security to reach the USD 27.62 resistance, with a potential gain of 13.2 %. Investors should not insist under USD 24.19 and place a stop loss order under this threshold.

Myriad Genetics, Inc. : Myriad Genetics, Inc. : Near a solid support area
Copyright (c) 2013 4-Traders.com



Partner Area
React to this article
 

Disclaimer : 4-Traders.com is not registered as a securities broker-dealer or investment adviser with any jurisdiction and is not providing any personalized financial, investment or tax advice. 4-Traders cannot assess or guarantee the suitability of any particular investment to any personal situation. Accordingly, you bear complete responsibility for your own investment, financial, and tax research and decisions and should seek the advice of a qualified professional prior to making any decisions based on 4-Traders' website information. This article is provided solely for informational purposes, and does not constitute an offer or solicitation to buy or sell any securities. All opinions expressed and information and data provided therein are subject to change without notice.

Advertisement
Financial Ratios

Size 2013e 2014e
Capitalization 2 504 M$ -
Company Value 2 129 M$ 2 067 M$
Valuation 2013e 2014e
PER (Price / EPS) 18,9x 17,1x
Capitalization / Revenue 4,18x 3,80x
EV / Revenue 3,56x 3,13x
EV / EBITDA 9,28x 8,28x
Yield (DPS / Price) - -
Profitability 2013e 2014e
Operating Margin (EBIT / Sales) 36,8% 36,9%
operating laverage (Delta EBIT / Delta Sales) 1,07x 1,02x
Net Margin (Net Profit / Revenue) 23,2% 22,8%
ROA (Net Profit / Asset) 23,2% 23,5%
ROE (Net Profit / Equities) 20,0% 19,5%
Rate of Dividend - -
Balance Sheet Analysis 2013e 2014e
CAPEX / Sales   1,92% 1,58%
Cash Flow / Sales (Taux d'autofinancement) 26,5% 27,4%
Capital Intensity (Assets / Sales) 1,00x 0,97x
Financial Leverage (Net Debt / EBITDA) -1,63x -1,75x
Income Statement Evolution
Myriad Genetics, Inc. : Income Statement Evolution
More Financials
EPS Revisions
Myriad Genetics, Inc. : EPS Revisions
Dynamic quotes  
ON
| OFF
Copyright © 2013 Surperformance. All rights reserved.